Inventiva Aktie [WKN DE: A2DLV9 / ISIN: FR0013233012]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Inventiva SA act ord

21.11.24		Inventiva reports 2024 Third Quarter Financial Information¹ (GlobeNewswire)
20.11.24		Combined General Meeting of December 11, 2024 - Availability of the preparatory documents (GlobeNewswire)
20.11.24		Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024 (GlobeNewswire)
15.11.24		Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® lat (GlobeNewswire)
30.10.24		Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH (GlobeNewswire)
21.10.24		Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024 (GlobeNewswire)
14.10.24		Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants (GlobeNewswire)
14.10.24		Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report (GlobeNewswire)
14.10.24		Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study (GlobeNewswire)
25.09.24		Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results (GlobeNewswire)
31.07.24		Inventiva Reports Preliminary 2024 First-Half Financial Information¹ (GlobeNewswire)
25.07.24		Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor (GlobeNewswire)
19.07.24		Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux (GlobeNewswire)
18.07.24		Inventiva announces a €20.1 million issuance of royalty certificates (GlobeNewswire)
05.07.24		Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position (GlobeNewswire)
21.06.24		Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024 (GlobeNewswire)
21.06.24		Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024 (GlobeNewswire)
30.05.24		Combined General Meeting of June 20, 2024 - Availability of the preparatory documents (GlobeNewswire)
30.05.24		Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024 (GlobeNewswire)
22.05.24		Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024 (GlobeNewswire)
21.05.24		Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update (GlobeNewswire)
16.05.24		Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH (GlobeNewswire)
13.05.24		Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with (GlobeNewswire)
03.04.24		Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F (GlobeNewswire)
28.03.24		Inventiva announces the nomination of Andre Turenne as Director (GlobeNewswire)
27.03.24		Inventiva reports its 2023 full-year results (GlobeNewswire)
22.03.24		Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results (GlobeNewswire)
18.03.24		Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D (GlobeNewswire)
13.03.24		Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D (GlobeNewswire)
07.03.24		Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed (GlobeNewswire)
15.02.24		Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3 (GlobeNewswire)
24.01.24		Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux (GlobeNewswire)
10.01.24		Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank (GlobeNewswire)
20.12.23		Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program (GlobeNewswire)
04.12.23		Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH (GlobeNewswire)
21.11.23		Inventiva reports 2023 Third Quarter Financial Information¹ (GlobeNewswire)
06.11.23		Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023 (GlobeNewswire)
28.09.23		Inventiva reports its 2023 first-half financial results and provides a corporate update (GlobeNewswire)
20.09.23		Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea (GlobeNewswire)
31.08.23		Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certifica (GlobeNewswire)
27.07.23		Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update (GlobeNewswire)
24.06.23		Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association (GlobeNewswire)
13.06.23		Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD (GlobeNewswire)
08.06.23		Inventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients (GlobeNewswire)
07.06.23		Inventiva announces five scientific presentations at the EASL International Liver Congress™ 2023 (GlobeNewswire)
26.05.23		Results of the votes of the Combined Shareholders’ General Meeting of May 25, 2023 (GlobeNewswire)
25.05.23		Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China (GlobeNewswire)
25.05.23		Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 25 May 2023 (GlobeNewswire)
16.05.23		Inventiva reports 2023 First Quarter Financial Information¹ and provides a corporate update (GlobeNewswire)
04.05.23		Statement of total voting rights and shares forming the company’s share capital as of April 17, 2023 (GlobeNewswire)

1 | Weiter

Newssuche

Inventiva Peer Group Nachrichten

17.06.20

Inventiva-Aktionäre machen nach Kursfeuerwerk kaum Kasse

Meistgelesene Nachrichten

voestalpine-Aktie mit Verlusten: Stabile Erdgasversorgung trotz möglicher Unterbrechungen aus Russland

NVIDIA-Aktie profitiert von starkem Plus bei Umsatz und Gewinn

SBO-Aktie rutscht deutlich ab: Schoeller-Bleckmann verzeichnet deutlichen Gewinneinbruch nach drei Quartalen

UNIQA steigert Ergebnis trotz Unwetterschäden - Trennung von Beteiligungen in Albanien, Kosovo und Nordmazedonien - Aktie profitiert

Neuer Rekord: Bitcoin klettert über 99.000 Dollar

Kryptorally setzt sich fort: Bitcoin, Dogecoin, Ethereum & Co. am Donnerstagmittag

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	24.11.2024 00:43
Kaufwert:	EUR
	Hinzufügen Speichern